Bristol Myers Squibb concludes sale of New York manufacturing facility
New York: Bristol Myers Squibb has completed the previously announced sale of its manufacturing facility in Syracuse, New York to LOTTE BIOLOGICS.
The divestiture is part of Bristol Myers Squibb’s ongoing evolution of its manufacturing network to support its product portfolio.
As part of the transaction, LOTTE BIOLOGICS has offered all employees at the site employment within its business. Additionally, LOTTE BIOLOGICS has acquired the Syracuse site’s operations and assets, which includes the property, plant, and equipment.
Bristol Myers Squibb has entered into a newly established contract manufacturing organization (CMO) relationship with LOTTE, under which LOTTE BIOLOGICS will manufacture product for Bristol Myers Squibb at the Syracuse facility.
Read also: Bristol Myers Squibb bags USFDA approval for plaque psoriasis oral treatment Sotyktu
The Bristol Myers Squibb Company is an American multinational pharmaceutical company headquartered in New York City. The company was founded in 1887 by William McLaren Bristol, E. R. Squibb, John Ripley Myers.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.